Selewski, David T. http://orcid.org/0000-0003-0358-0760
Askenazi, David J.
Kashani, Kianoush
Basu, Rajit K.
Gist, Katja M.
Harer, Matthew W.
Jetton, Jennifer G.
Sutherland, Scott M.
Zappitelli, Michael
Ronco, Claudio
Goldstein, Stuart L.
Mottes, Theresa Ann
Article History
Received: 2 June 2020
Revised: 24 September 2020
Accepted: 15 October 2020
First Online: 12 January 2021
Compliance with ethical standards
:
: The authors have no quality improvement-related conflicts of interest to report that would have affected the writing of this publication. For AKI-related research, Michael Zappitelli is a member of the AKI adjudication committee for an industry-sponsored study on NGAL as an AKI biomarker (Bioporto Inc.). David Selewski has participated in AKI adjudication for an industry-sponsored study on NGAL as an AKI biomarker (Bioporto Inc.). David J Askenazi is consultant for Baxter, CHF solutions, Medtronic, AKI Foundation, and Bioporto. Rajit Basu is a consultant for Baxter, Biomerieux, and BioPorto. Theresa Mottes is consultant for Baxter and Medtronic. Claudio Ronco consulted or participated in advisory boards for ASTUTE, ASAHI, Baxter, Biomerieux, OCD, GE, FMC, Cytosorbents, B. Braun, Medtronic, Jafron, and Toray over the last 3 years.
Free to read: This content has been made available to all.